雷贝拉唑联合莫沙必利对功能性消化不良患者胃动力指标、胃肠激素的影响

doi:10.3969/j.issn.1671-7171.2025.03.024

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1175 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the effects of rabeprazole combined with mosapride on gastric emptying rate, intestinal emptying rate, gastric motility indicators, and gastrointestinal hormones in patients with functional dyspepsia (FD).【Methods】 A total of 102 patients with FD were randomly divided into two groups: the observation group and the control group, with 51 patients in each group. Patients in the control group received only rabeprazole treatment, while the observation group was treated with rabeprazole combined with mosapride. The gastric emptying rate, intestinal emptying rate, gastric motility indicators [plasma leptin (LEP), motilin (MTL), corticotropin-releasing hormone (CRH)], and gastrointestinal hormones [gastrin (GAS), substance P (SP), vasoactive intestinal peptide (VIP)] levels were compared between the two groups before and after treatment. The incidence of adverse reactions was also recorded and compared.【Results】 After treatment, the observation group showed significantly better gastric emptying rate, intestinal emptying rate, gastric motility indicators, and gastrointestinal hormone levels compared to the control group (P<0.05). The total incidence of adverse reactions in the observation group was 5.88% (3/51), significantly lower than that of the control group at 19.61% (10/51), with a statistically significant difference (P<0.05).【Conclusion】 Rabeprazole combined with mosapride can significantly improve gastric and intestinal emptying rates, gastric motility, and gastrointestinal hormone levels in FD patients, while reducing the incidence of adverse reactions. It is worthy of clinical promotion and application.

Key words： Dyspepsia Rabeprazole Drug Therapy, Combination Gastrointestinal Motility

Received: 28 August 2024

PACS:

R573

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xianle
	XU Feng

Cite this article:

CHEN Xianle,XU Feng. Effect of Rabeprazole Combined with Mosapride on Gastric Motility Indicators and Gastrointestinal Hormones in Patients with Functional Dyspepsia[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 450-452.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.024 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/450

[1] 张雯,陈新波. 匹维溴铵、伊托必利与多潘立酮治疗功能性消化不良的效果和用药安全性[J].中国老年学杂志,2022,42(11):2699-2701.
[2] 董丽娟,贺继东,赵文亭,等. 莫沙必利联合氟哌噻吨美利曲辛治疗功能性消化不良对患者近端胃舒张及胃排空功能影响分析[J].临床误诊误治,2020,33(3):48-52.
[3] 唐欢,陈扬,郑学颖. 雷贝拉唑联合微生态制剂治疗老年功能性消化不良的临床疗效及对患者血清GHR、AchE水平的影响[J].中国老年学杂志,2022,42(19):4684-4687.
[4] 王荣荣. 莫沙必利片联合米曲菌胰酶片治疗老年功能性消化不良的效果分析[J].中国药物与临床,2021,21(2):298-299.
[5] 黄更珍,张耀丹,唐小波,等. 雷贝拉唑联合舒肝解郁胶囊及益生菌治疗功能性消化不良及对胃肠激素的影响[J].川北医学院学报,2020,35(5):798-801.
[6] 李贻弘,苏青,刘劲松,等. 匹维溴铵与雷贝拉唑治疗腹泻型肠易激综合征与功能性消化不良重叠患者的随机对照研究[J].临床消化病杂志,2021,33(6):423-427.
[7] 李美荣,王晓伟,牛美娜,等. 雷贝拉唑、莫沙必利联合米曲菌胰酶治疗反流性食管炎伴功能性消化不良的疗效[J].中国新药与临床杂志,2021,40(7):515-519.
[8] 杨婷,刘文卿,刘金枝,等. 功能性消化不良患者心理状态与肠道菌群失调、胃肠动力的相关性[J].医学临床研究,2023,40(12):1916-1918.
[9] 包瑞玲,刘文滨,丁瑞峰,等. 舒肝解郁胶囊联合莫沙必利对功能性消化不良大鼠胃黏膜CRF、C-KIT表达的影响[J].中成药,2021,43(2):506-509.
[10] 马治娥,赵文娟,陈帅. 复方消化酶治疗功能性消化道不良的疗效及对患者胃肠激素、LEP、CCK水平的影响[J].医学临床研究,2024,41(2):296-298.
[11] 李松财. 氟哌噻吨美利曲辛片结合匹维溴铵对更年期功能性消化不良患者植物神经及胃肠道功能的影响[J].中国妇幼保健,2021,36(2):426-429.
[12] 甘晓菁,魏巧燕. 雷贝拉唑联合莫沙必利治疗功能性消化不良的临床效果及对胃肠动力的影响[J].中外医学研究,2020,18(30):47-49.
[13] 胡云富. 雷贝拉唑联合伊托必利治疗功能性消化不良的效果及安全性[J].中国医药导报,2022,19(10):159-162.
[14] 张静瑜,吕丹丹,谢燕东. 雷贝拉唑联合莫沙必利治疗功能性消化不良患者的疗效观察[J].实用临床医药杂志,2020,24(16):43-46.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 546-548.